Commit Biologics ApS
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Commit Biologics ApS - overview
Established
2021
Location
Aarhus, -, Denmark
Primary Industry
Biotechnology
About
Based in Aarhus, Denmark, and founded in 2021 by co-founders Nick S. Laursen, Dennis V. Pedersen, Heidi Gytz Olesen, and Mikael Winkler, Commit Biologics ApS operates as a biotechnology research company, that develops a novel immunotherapy platform for the treatment of cancer. In March 2026, Commit Biologics ApS raised EUR 21.
5 million in seed funding from Novo Holdings, Bioqube Ventures, and Korys. Commit Biologics' portfolio is BiCE technology, a platform designed to activate the complement system against cancer cells. The company employs bi-specific antibodies to activate the complement cascade, facilitating targeted destruction of tumor cells while promoting an immune response against cancer. Its mechanism of action triggers tumor cell killing while also modulating the tumor microenvironment.
The company will use the seed funding to progress its therapies into clinical development.
Current Investors
Novo Holdings, Bioqube Ventures, Innovation Fund Denmark
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biotechnology, Oncology/Cancer Treatment, Medical Software
Website
www.commitbio.com/
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.